Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia in patients on dialysis Investment comes ahead of Phase 2b topline data, expected in H1 2027 Redwood City, California […]
Investment supports application of ViaNautis’ polyNaut® platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrier Adds a new high-value CNS indication and provides further validation of polyNaut® as a versatile platform for precise, non-viral delivery of genetic medicines Cambridge, UK – 9 September 2026 – ViaNautis Bio (“ViaNautis”), the […]
Sofinnova combines its sector expertise with AWS’s AI and cloud services to help life sciences companies scale faster The collaboration expands Sofinnova’s proprietary AI platform, Sofia, including a new founder-facing version PARIS, France – June 10, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, […]
ARE vaccines coming in from the cold? That’s the question this week after Eli Lilly splashed out almost $4 billion on three vaccine biotechs, two of which are in the early stage of clinical development. All are developing jabs for or related to infectious diseases. Why’s this a big deal? Because everyone knows that […]
